Press Release
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
NEW YORK , April 7, 2021 /PRNewswire/ -- atai Life Sciences ( " atai" or the " Company"), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to
April 7, 2021
Press Release
Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia
NEW YORK, April 6, 2021 /PRNewswire/ -- Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has
April 6, 2021
Press Release
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
NEW YORK and TOKYO, March 16, 2021 /PRNewswire/ -- Perception Neuroscience (Perception), an atai Life Sciences (atai) company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd. (Otsuka), announce a collaboration and licensing agreement for
March 16, 2021
Press Release
IntelGenx Announces Strategic Partnership with atai Life Sciences and Proposed TSX Graduation
SAINT LAURENT, Quebec, and NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX ) (OTCQB:IGXT) (the “ Corporation ”) today announced that its wholly owned subsidiary, IntelGenx Corp. (“ IntelGenx ”), a leader in pharmaceutical films, has agreed to the terms of a
March 15, 2021
Press Release
DemeRx Receives MHRA Approval for DMX-1002 (Ibogaine) to Commence Phase 1/2a Study as First Clinical Trial in Opioid Use Disorder in the UK
NEW YORK, March 10, 2021 /PRNewswire/ -- DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency
March 10, 2021
Press Release
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
NEW YORK, March 3, 2021 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D
March 3, 2021
Displaying 85 - 90 of 107